Thomas Tillett | Chief Executive Officer
MBF Therapeutics

Thomas Tillett, Chief Executive Officer, MBF Therapeutics

Thomas Tillett – Cofounder and CEO of MBF Therapeutics, an immunotherapeutics company that has developed and patented an innovative, proprietary T-Max™ DNA vaccine platform to deliver commercial protective vaccines that provide safe, durable, heterologous protection against endemic, emerging and re-emerging diseases of global concern to livestock and companion animals, with significant translational opportunities in human health.  Tom is the founder and Executive Director of Sustained Acts, a Christian non-profit focusing on sustainable projects in Africa and serves on the Friends of Kijabe Hospital Board of Directors. Mr. Tillett was founder, and CEO of RHeoGene. As RheoGene CEO, he and his team created the RheoSwitch® Therapeutic System (RTS) that led to the first human clinical trial of a small molecule-induced gene regulation system. In 2007, he successfully completed the merger of RheoGene Inc. with Intrexon Corporation who has continued the development of RTS through a various clinical trials for cancer and other important therapeutic indications. In April, 2019 the FDA announced that the RheoSwitch Therapeutic System for glioma blastoma was approved for Fast Track designation. Mr. Tillett has served on the board of numerous non-profits including; University of North Carolina General Alumni Association, Impact Thrift Stores, Chelten Church Elder Board, and the American School of Paris. He was also elected to the Hatboro-Horsham Hall of Fame in 2017.

Appearances:



Day 2 - Wednesday 3rd April @ 12:10

Next Generation DNA vaccines for ‘One Health’ – Title TBC

last published: 26/Feb/24 13:16 GMT

back to speakers